Study Suggests Older Adults Can Safely Discontinue Statins for Primary Prevention

A study published in *Lancet Healthy Longevity* indicates that adults aged 75 or older taking statins solely for primary prevention of cardiovascular disease may safely discontinue the therapy without increasing all-cause mortality over three years. The French SAGA/SITE trial, involving 1,160 participants, found similar all-cause mortality rates (7.9% vs. 7.2%) and major atherosclerotic cardiovascular disease events (4.4% vs. 5.0%) between those who continued and those who stopped statins. These findings support individualized discussions between clinicians and patients regarding deprescribing based on preferences, comorbidities, and treatment goals.

Context

Statins are commonly prescribed to lower cholesterol and reduce the risk of heart disease, especially in older adults. However, their effectiveness in those aged 75 and older for primary prevention has been debated. Previous studies have not definitively addressed whether discontinuing statins affects overall mortality in this age group, making this new research particularly relevant.

Why it matters

This study is significant as it challenges the long-standing practice of prescribing statins to older adults for primary prevention of cardiovascular disease. It suggests that many older patients may not need to continue this medication, potentially reducing unnecessary drug use and associated side effects. The findings could lead to changes in clinical guidelines and patient management strategies for older adults.

Implications

If clinicians adopt the study's recommendations, many older adults may experience improved quality of life by avoiding unnecessary medication. This could also lead to reduced healthcare costs associated with long-term statin use. However, patients with specific health conditions may still require careful consideration regarding their treatment plans.

What to watch

Healthcare providers may begin to reassess statin prescriptions for older patients, leading to more personalized treatment plans. The study could prompt further research into the long-term effects of stopping statins in older populations. Observing how clinical practices evolve in response to these findings will be important in the coming months.